Linked CIViC Profile: EGFR L858R
Evidence Level Distribution
Level A: 2Level B: 13Level C: 3Level D: 19
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Afatinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dacomitinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Afatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Afatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | 3 |
| B | Prognostic | Supports | Better Outcome | Lung Non-small Cell Carcinoma | 3 | |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Afatinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Lapatinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dacomitinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Neratinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Canertinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Gefitinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Gefitinib,Multikinase Inhibitor AEE788,Erlotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Erlotinib | 3 |